The Role Of Telomeres In The Treatment And Detection Of Early AMD (Age Related Macular Degeneration) And Alzheimers Disease

Dr. Tom Dow

NP

Summary
  • Rationale of a trial testing TA-65 in AMD.
  • Relative void in treating options for early AMD.
  • Results of our pilot study of TA-65 in early AMD.
Transcript
Joseph M. Raffaele, M.D.

I have with me today on the Telomere Summit, Dr Tom Dow, who is a Medical and Surgical Ophthalmologist and practiced for over 40 years in Clinical Ophthalmology. He maintains a clinical appointment at the University of Wisconsin, Madison, and is a member of McPherson Eye Research Institute. He has also worked as a physician scientist, conducting clinical trials. Since 2000 he has had a research interest in the role of infection, specifically mycobacteria and paratuberculosis, or MAP, in a broad range of human inflammatory diseases. Also, he has studied clinical applications arising from telomere biology and telomerase, His work testing oral telomerase activator in age-related macular degeneration has led to interest by the National Eye Institute. Welcome, Tom, to the Telomere Summit. And really excited to speak to you. I remember when your study came out in 2016, we had a brief conversation in Las Vegas about it. But I’ve got all sorts of questions, and looking forward to this conversation.

Related Videos

Telomeres & Telomerase Activation; Connecting the Dots

Ron Rothenberg, MD

Telomere Biology And It’s Application To Environmental Toxins And Chronic Inflammatory Disorders

Gordon Crozier, DO

Purchase Now

CARD DETAILS

TOTAL: $

Sign-in

Login to get access to DrSummits wide selection of expert videos, your summit or video purchases.

Cart

Your cart is currently empty.

Return to shop

Sign up

Name*
Password*
Consent*

Already have an account? Log In